The chemotherapeutic agent bortezomib induces the formation of stress granules

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Fournier, Marie Josée ^a,b   Gareau, Cristina ^a,b   Mazroui, Rachid ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FRAGILE X MENTAL RETARDATION PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEME REGULATED INHIBITOR KINASE; HUR PROTEIN; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E; PROTEIN KINASE R; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL GRANULE; CELL STRESS; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; HELA CELL; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION;

EID: 77951598447     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-12     Document Type: Article

References (47)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5(5):417-421. 10.1016/S1535-6108(04)00120-5, 15144949.
2. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4(5):349-360. 10.1038/nrc1361, 15122206.
3. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(3):855-860. 10.1073/pnas.94.3.855, 19603, 9023346.
4. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995, 217(3):1070-1077. 10.1006/bbrc.1995.2878, 8554559.
5. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. The Journal of biological chemistry 1997, 272(20):12893-12896. 10.1074/jbc.272.20.12893, 9148891.
6. Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008, 14(16):5116-5123. 10.1158/1078-0432.CCR-07-4506, 2774251, 18698029.
7. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11(4-5):164-179. 10.1016/j.drup.2008.08.002, 18818117.
8. Richardson PG. A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert opinion on pharmacotherapy 2004, 5(6):1321-1331. 10.1517/14656566.5.6.1321, 15163277.
9. Richardson PG, Anderson KC. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003, 1(10):596-600.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England journal of medicine 2003, 348(26):2609-2617. 10.1056/NEJMoa030288, 12826635.
11. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10(5):361-369.
12. Richardson PG, Hideshima T, Mitsiades C, Anderson K. Proteasome inhibition in hematologic malignancies. Annals of medicine 2004, 36(4):304-314. 10.1080/07853890410030877, 15224657.
13. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008, 8(7):1053-1072. 10.1586/14737140.8.7.1053, 18588451.
14. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. The potential of proteasome inhibitors in cancer therapy. Expert opinion on investigational drugs 2008, 17(6):879-895. 10.1517/13543784.17.6.879, 18491989.
15. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular cancer therapeutics 2006, 5(3):665-675. 10.1158/1535-7163.MCT-05-0147, 16546981.
16. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23(3):630-639. 10.1200/JCO.2005.11.030, 15659509.
17. Tang ZY, Wu YL, Gao SL, Shen HW. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. The Journal of surgical research 2008, 145(1):111-123. 10.1016/j.jss.2007.03.061, 17714734.
18. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34(Pt 1):7-11.
19. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nature reviews 2005, 6(4):318-327. 10.1038/nrm1618, 15803138.
20. Barber GN. The dsRNA-dependent protein kinase, PKR and cell death. Cell death and differentiation 2005, 12(6):563-570. 10.1038/sj.cdd.4401643, 15846372.
21. Lu L, Han AP, Chen JJ. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Molecular and cellular biology 2001, 21(23):7971-7980. 10.1128/MCB.21.23.7971-7980.2001, 11689689, 99965.
22. Anderson P, Kedersha N. Visibly stressed: the role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress Chaperones 2002, 7(2):213-221. 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2, 514820, 12380690.
23. Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends in biochemical sciences 2008, 33(3):141-150.
24. Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Molecular cell 2009, 36(6):932-941. 10.1016/j.molcel.2009.11.020, 20064460.
25. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5(5):429-441. 10.1016/S1535-6108(04)00115-1, 15144951.
26. Gardner LB. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Molecular and cellular biology 2008, 28(11):3729-3741. 10.1128/MCB.02284-07, 2423288, 18362164.
27. Kedersha N, Chen S, Gilks N, Li W, Miller IJ, Stahl J, Anderson P. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Molecular biology of the cell 2002, 13(1):195-210. 10.1091/mbc.01-05-0221, 65082, 11809833.
28. Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, Golan DE, Anderson P. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol 2000, 151(6):1257-1268. 10.1083/jcb.151.6.1257, 2190599, 11121440.
29. Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW. Trapping of messenger RNA by Fragile × Mental Retardation protein into cytoplasmic granules induces translation repression. Human molecular genetics 2002, 11(24):3007-3017. 10.1093/hmg/11.24.3007, 12417522.
30. Mazroui R, Sukarieh R, Bordeleau ME, Kaufman RJ, Northcote P, Tanaka J, Gallouzi I, Pelletier J. Inhibition of ribosome recruitment induces stress granule formation independently of eukaryotic initiation factor 2alpha phosphorylation. Molecular biology of the cell 2006, 17(10):4212-4219. 10.1091/mbc.E06-04-0318, 1635342, 16870703.
31. McInerney GM, Kedersha NL, Kaufman RJ, Anderson P, Liljestrom P. Importance of eIF2alpha phosphorylation and stress granule assembly in alphavirus translation regulation. Molecular biology of the cell 2005, 16(8):3753-3763. 10.1091/mbc.E05-02-0124, 1182313, 15930128.
32. Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, Dember LM, Anderson P. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Molecular biology of the cell 2004, 15(12):5383-5398. 10.1091/mbc.E04-08-0715, 532018, 15371533.
33. Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Molecular biology of the cell 2007, 18(7):2603-2618. 10.1091/mbc.E06-12-1079, 1924830, 17475769.
34. Tsai NP, Ho PC, Wei LN. Regulation of stress granule dynamics by Grb7 and FAK signalling pathway. The EMBO journal 2008, 27(5):715-726. 10.1038/emboj.2008.19, 2265756, 18273060.
35. Anderson P, Kedersha N. RNA granules. J Cell Biol 2006, 172(6):803-808. 10.1083/jcb.200512082, 2063724, 16520386.
36. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nature cell biology 2008,
37. Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes & development 2007, 21(24):3381-3394. 2113037, 18079183, 10.1101/gad.461107.
38. Yerlikaya A, Kimball SR, Stanley BA. Phosphorylation of eIF2alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. The Biochemical journal 2008, 412(3):579-588. 10.1042/BJ20080324, 2842126, 18290760.
39. McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, Chen JJ, Anderson P, Kaufman RJ. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. The Journal of biological chemistry 2005, 280(17):16925-16933. 10.1074/jbc.M412882200, 15684421.
40. Dang Y, Kedersha N, Low WK, Romo D, Gorospe M, Kaufman R, Anderson P, Liu JO. Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. The Journal of biological chemistry 2006, 281(43):32870-32878. 10.1074/jbc.M606149200, 16951406.
41. Mokas S, Mills JR, Garreau C, Fournier MJ, Robert F, Arya P, Kaufman RJ, Pelletier J, Mazroui R. Uncoupling stress granule assembly and translation initiation inhibition. Molecular biology of the cell 2009, 20(11):2673-2683. 10.1091/mbc.E08-10-1061, 2688547, 19369421.
42. Berlanga JJ, Herrero S, de Haro C. Characterization of the hemin-sensitive eukaryotic initiation factor 2alpha kinase from mouse nonerythroid cells. The Journal of biological chemistry 1998, 273(48):32340-32346. 10.1074/jbc.273.48.32340, 9822714.
43. Mellor H, Flowers KM, Kimball SR, Jefferson LS. Cloning and characterization of cDNA encoding rat hemin-sensitive initiation factor-2 alpha (eIF-2 alpha) kinase. Evidence for multitissue expression. The Journal of biological chemistry 1994, 269(14):10201-10204.
44. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. Journal of the National Cancer Institute 2000, 92(19):1564-1572. 10.1093/jnci/92.19.1564, 11018092.
45. Lu L, Han AP, Chen JJ. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Molecular and cellular biology 2001, 21(23):7971-7980. 10.1128/MCB.21.23.7971-7980.2001, 99965, 11689689.
46. Kim WJ, Back SH, Kim V, Ryu I, Jang SK. Sequestration of TRAF2 into stress granules interrupts tumor necrosis factor signaling under stress conditions. Molecular and cellular biology 2005, 25(6):2450-2462. 10.1128/MCB.25.6.2450-2462.2005, 1061607, 15743837.
47. Mazroui R, Di Marco S, Clair E, von Roretz C, Tenenbaum SA, Keene JD, Saleh M, Gallouzi IE. Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. J Cell Biol 2008, 180(1):113-127. 10.1083/jcb.200709030, 2213623, 18180367.